A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

NCT04749394 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Camrelizumab, PD-1 monoclonal antibody
DRUG: Apatinib, VEGFR2 antibody

Sponsor

Chinese Academy of Medical Sciences